Although there is no cure for narcolepsy, medication and lifestyle changes can help manage the symptoms. Medicines that ...

Harmony Biosciences' Wakix shows promise for significant revenue growth. Find out why HRMY stock’s profitability and pipeline ...

Central nervous system (CNS) specialist Neuraxpharm Group has acquired Provigil (modafinil) and Nuvigil (armodafinil), both of which are indicated for the treatment of excessive daytime sleepiness ...

Axsome Therapeutics, Inc. AXSM announced that the FDA has approved Symbravo (meloxicam and rizatriptan) for the acute ...

Avadel Pharmaceuticals expects its narcolepsy treatment Lumryz to drive strong revenue growth in the fourth quarter and into 2025, preliminary earnings show. The Dublin-based company anticipates ...

A leading sleep expert highlighted the drug's transformative potential across narcolepsy subtypes and idiopathic hypersomnia (IH), suggesting it could significantly improve wakefulness compared to ...

Sales of its narcolepsy drug, LUMRYZ rose by 150% YoY. AVDL expects net product revenue for 2025 in the range of $240 million to $260 million. Get the Real Story Behind Every Major Earnings Report ...

Wake up and go to sleep The irony of these two narcolepsy drugs that work to normalise the sleep-wake cycle is that they have to be taken twice per night. Patients have the first dose before they ...

Meloxicam is a nonsteroidal, anti-inflammatory molecule developed with Axsome’s Molecular Solubility Enhanced Inclusion ...

DUBLIN - Avadel Pharmaceuticals plc (NASDAQ: NASDAQ:AVDL), a company specializing in the development of transformative medicines with a market capitalization of $1.05 billion, has announced ...

E-2086 is under clinical development by Eisai and currently in Phase I for Narcolepsy. According to GlobalData, Phase I drugs for Narcolepsy have an 80% phase transition success rate (PTSR) indication ...